Related Experiment Video
Updated: Feb 9, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
Panagiotis A Konstantinopoulos1, Ursula A Matulonis2
1Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
Abstract:
PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and BRCA-mutated (BRCAm) cancer treatment. Clin Cancer Res; 24(17); 4062-5. ©2018 AACRSee related article by Ison et al., p. 4066.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors are revolutionizing ovarian cancer treatment, particularly for BRCA-mutated cancers. These drugs are now approved for maintenance therapy after chemotherapy in recurrent ovarian cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian cancer, especially the high-grade serous subtype, is characterized by homologous recombination (HR) deficiencies.
- Aberrant DNA repair pathways are a hallmark of these tumors, creating therapeutic vulnerabilities.
Purpose of the Study:
- To review the clinical impact and therapeutic potential of PARP inhibitors in ovarian cancer.
- To highlight the role of HR deficiency and BRCA mutations in treatment response.
Main Methods:
- Review of clinical trial data and preclinical research on PARP inhibitors.
- Analysis of mechanisms of action, including synthetic lethality in BRCA-mutated cells.
Main Results:
- PARP inhibitors have demonstrated significant efficacy in treating ovarian cancer.
- These agents are approved for maintenance therapy in recurrent ovarian cancer following platinum chemotherapy response.
- Treatment is particularly effective in patients with BRCA-mutated (BRCAm) ovarian cancer.
Conclusions:
- PARP inhibitors represent a major advancement in ovarian cancer therapy.
- Targeting DNA repair deficiencies, especially in BRCAm tumors, is a key strategy.
- Further research is ongoing to expand the utility of PARP inhibitors.
More Related Videos
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
04:07Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
Transformers
The iron core has a substantial relative permeability. Therefore, the magnetic field lines generated due to the current in one winding are almost entirely confined within the core, such that the same magnetic flux permeates each turn of both...
Transformation
Ovarian Cycle
Transformations of Functions I